Life sciences briefing: Tuesday, Dec. 18, 2007
TODAY’S HEADLINES:
Elixir Pharma sets IPO range, seeks up to $92M for anti-aging drugs (Edgar)
Deltanoid Pharma raises $12M for kidney drugs (PDF release)
CovX, cancer and diabetes-drug biotech, acquired by Pfizer (release)
Affymetrix pays $75M for reagent maker USB (release)
Merrion Pharma postpones U.S. IPO, raises €5.6M in Dublin offering (Irish Independent)
Isis spinout Altair raising first round for asthma drugs (release)
“Human hydration” sensor maker Cantimer names Robin Stracey CEO (release)
Sensimed raises CHF 8M for glaucoma diagnostics (PE Hub)
Deltanoid Pharma… Continue Reading
ProCertus pulls in $2.3M for prevention of chemo, radiation side effects
ProCertus BioPharm, a Madison, Wis., company developing drugs to minimize the side effects of radiation and chemotherapy, raised $2.3 million in a first round of financing. The company will use the money to begin human tests of products such as DermX, which is supposed to prevent radiation-therapy induced dermatitis.
The round was led by Venture Investors, a significant Midwest-based healthcare and IT venture firm. Existing investors including the Novartis Venture Fund also joined the round.
These… Continue Reading
TomoTherapy, cancer-treatment system maker, gets enthusiastic IPO reception
TomoTherapy, a Madison, Wis.-based maker of imaging and radiation-treatment systems for cancer therapy, raised $222.3 million in an initial offering after its shares priced higher than the company’s original range.
TomoTherapy shares, which now trade under the symbol TTPY, priced at $19, well above the company’s expected range of $15 to $17, yielding net proceeds to the company of roughly $185 million. The stock opened this morning at $24. TomoTherapy makes and sells integrated devices that… Continue Reading